Gadelha, Mônica R <br/><br/>
Pasireotide versus continued treatment with octreotide or lanreotide in patients with inadequately controlled acromegaly (PAOLA): a randomised, phase 3 trial.  [electronic resource] 

 -  The lancet. Diabetes & endocrinology  Nov 2014 
 - 875-84 p.  digital 
<br/><br/> Publication Type: Clinical Trial, Phase III; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't 
<br/><br/><label>ISSN: </label>2213-8595 
<br/><br/><label>Standard No.: </label>10.1016/S2213-8587(14)70169-X  doi 
<br/><br/><label>Subjects--Topical Terms: </label><br/>Acromegaly--drug therapy<br/>Adolescent<br/>Adult<br/>Aged<br/>Aged, 80 and over<br/>Female<br/>Human Growth Hormone--blood<br/>Humans<br/>Insulin-Like Growth Factor I--analysis<br/>Male<br/>Middle Aged<br/>Octreotide--therapeutic use<br/>Peptides, Cyclic--therapeutic use<br/>Somatostatin--administration & dosage<br/>Treatment Outcome<br/>Young Adult